[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623768":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Glaukos Corporation","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Model G2-TRIO",null,"Subjects receive a Travoprost intracameral implant with the Model G2-TRIO",[13],"Combination Product: Travoprost",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"COMBINATION_PRODUCT","Travoprost","Travoprost intracameral implant, 75mcg administered using the sterile, single-dose updated inserter (Model G2-TRIO)",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Study Director","CONTACT","949-739-8749","ClinicalResearch@glaukos.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":10},"Glaukos Investigative Site","RECRUITING","Kenosha","Wisconsin","53140","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-87.82119,42.58474,{"lat":39,"lon":38},{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100623768","observational-trial-of-the-updated-inserter-for-the-travoprost-intracameral-implant-75mcg-100623768",false,"NCT07400926","Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg","Clinical In-use Observational Trial to Evaluate the Updated Inserter for the Travoprost Intracameral Implant 75 mcg","TRIO","Inclusion Criteria:\n\n* Diagnosis of Open-angle glaucoma\n* 18 years of age or older\n\nExclusion Criteria:\n\n* Subject who is breast-feeding or pregnant","ALL","18 Years",{"count":54,"type":55},30,"ESTIMATED","OBSERVATIONAL","Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)",[59,60],"Open Angle Glaucoma (OAG)","Ocular Hypertension (OH)",[62,63],"Glaucoma","Ocular Hypertension","2026-02-24",{"date":66,"type":67},"2026-02-27","ACTUAL",{"date":69,"type":67},"2025-12-17",{"date":71,"type":55},"2026-07",{"name":5,"class":6},1]